Celexa and Myeloma recurrence - a phase IV clinical study of FDA data

Summary:

Myeloma recurrence is reported as a side effect among people who take Celexa (citalopram hydrobromide), especially for people who are male, 50-59 old, also take Revlimid, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Myeloma recurrence when taking Celexa. It is created by eHealthMe based on reports of 49,596 people who have side effects when taking Celexa from the FDA, and is updated regularly.

What is Celexa?

Celexa has active ingredients of citalopram hydrobromide. It is often used in depression. eHealthMe is studying from 56,390 Celexa users. Check the latest studies of Celexa.

What is Myeloma recurrence?

Myeloma recurrence (recurrence of cancer of the plasma cells - a kind of white blood cell) is found to be associated with 176 drugs and 54 conditions by eHealthMe. Check the latest studies of Myeloma recurrence.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

49,596 people reported to have side effects when taking Celexa.
Among them, 13 people (0.03%) have Myeloma recurrence.

Among these 13 people:

What is the gender of people who have Myeloma recurrence when taking Celexa? *

female: 0.0 %
male: 100 %

What is the age of people who have Myeloma recurrence when taking Celexa? *

What are other drugs people take besides Celexa? *

What are other side effects people have besides Myeloma recurrence? *

Diabetes: 13 people, 100.00%
Osteonecrosis Of Jaw (death of bone of jaw): 13 people, 100.00%
Pain: 13 people, 100.00%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 13 people, 100.00%
General Physical Health Deterioration (weak health status): 13 people, 100.00%
Bone Disorder: 13 people, 100.00%
Decreased Interest: 13 people, 100.00%
Constipation: 11 people, 84.62%
Mitral Valve Incompetence (inefficient heart valve): 11 people, 84.62%
Intervertebral Disc Protrusion (spinal disc protrusion): 11 people, 84.62%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 7 people, 53.85%
Pneumocystis Jiroveci Infection (fungal infection of the lungs): 1 person, 7.69%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Celexa and have Myeloma recurrence?

- Check whether Myeloma recurrence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Celexa:

Celexa (56,390 reports)

Browse all side effects of Celexa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Myeloma recurrence:

Myeloma recurrence (176 drugs)

Browse all the conditions that are associated with Myeloma recurrence:

Myeloma recurrence (54 conditions)

Related publications that referenced our studies

Hosseini, S. H., & Ahmadi, A., "Peripheral edema occurring during treatment with risperidone combined with citalopram", Case reports in medicine, 2012 Jan .
Hosseini, S. H., & Ahmadi, A., "Peripheral edema occurring during treatment with risperidone combined with citalopram", Case reports in medicine, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on citalopram hydrobromide (the active ingredients of Celexa) and Celexa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.